Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin

References

• Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411–2420
   PubMed Web of Science ®Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261–1275
   PubMed Web of Science ®Google Scholar
• Hamdalla J, Steinhubl SR. Oral antiplatelet therapy for percutaneous coronary revascularization. Catheter Cardiovasc Interv 2007; 69: 637–642
   PubMedGoogle Scholar
• Grescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA 100 closure time to predict cardiovascular events in aspirin treated cardiovascular patients: A meta-analysis of 19 studies comprising 3003 patients. Thromb Haemost 2008; 99: 1129–1131
   PubMedGoogle Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolilo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trek D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822–1834
   PubMed Web of Science ®Google Scholar
• Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E, Montalescot G. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1year after stenting (ARCTIC) study. Am Heart J 2011; 161: 5–12
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279–286
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351–359
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopiodgrel treatment. Thromb Haemost 2008; 99: 121–126
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T, Mehilli J, Voqt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–856
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Gori AM, Marcucci R, Giqlioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839–1847
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754–762
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: 489–493
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am CollCArdiol 2005; 46: 638–645
   Google Scholar
• Wallen NH, Ladjevardi M, Albert J, Broijersen A. Influence of different anticoagulants on platelet aggregation in whole blood: A comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997; 87: 151–157
   PubMed Web of Science ®Google Scholar
• Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781–788
   PubMed Web of Science ®Google Scholar
• Belcher PR, Muriithi EW, Day SP, Wheatley DJ. Platelet aggregatory responses to low-dose collagen are maintained in Hirudin-anticoagulated whole blood for 24 h when stored at room temperature. Platelets 2001; 12: 34–36
   PubMed Web of Science ®Google Scholar
• Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141–152
   PubMed Web of Science ®Google Scholar
• Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y12 antagonists. Thromb Haemost 2008; 99: 1127–1129
   PubMed Web of Science ®Google Scholar
• Pittens CA, Bouman HJ, van Werkum JW, ten Berg JM, Hackeng CM. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. J Thromb Haemost 2009; 7: 1928–1932
   Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensin GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009; 119: 237–342
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 2008; 52: 1128–1133
   PubMed Web of Science ®Google Scholar
• Marrcucci R, Giusti B, Paniccia R, Gori AM, Saracini C, Valente S, Giqlioli C, Parodi G, Antoniucci D, Gensini GF, Abbate R, High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 2012;Epub
   Google Scholar
• Jeong YH, Pakr Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyper-reactive platelet phenotype. Heart 2012; 98: 343
   PubMedGoogle Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97: 983–990
   PubMedGoogle Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, white J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–965
   PubMed Web of Science ®Google Scholar
• Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20: 7–11
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12: 1255–1259
   PubMed Web of Science ®Google Scholar
• Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, Ikeda T, Yamacoto H, Akao M, Furukawa Y, Shizuta S, Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishimoto N, Ouchi C, Morimoto T, Kita T, Kimura T. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009; 73: 336–342
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903–1910
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992–1000
   PubMed Web of Science ®Google Scholar
• Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, Hong MK, Seo MK, Youn TJ, Chae IH, Choi DJ, Jang Y. Comparison of 2 point of care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011; 161: 383–390
   PubMed Web of Science ®Google Scholar
• Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Cilostazol attenuates on treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: A genetic substudy of the CILON-T randomized controlled trial. Heart 2011; 97: 641–647
   PubMedGoogle Scholar